DeepMed Research

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia

Phase 4

Completed

Conditions: Anemia
Neoplasms

Interventions: Drug: Epoetin alfa 450 IU/kg once a week
Drug: Epoetin alfa 150 IU/kg 3 times a week
Drug: Epoetin alfa 450 IU/kg once a week (QW)
Drug: Epoetin alfa 150 IU/kg 3 times a week (TIW)

First Posted Date: 2011-07-15

Last Posted Date: 2012-04-05

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 504

Registration Number: NCT01394991

A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Canagliflozin 300mg
Drug: Canagliflozin 300mg/Canagliflozin 150mg
Drug: Placebo
Drug: Canagliflozin 300mg/Placebo

First Posted Date: 2011-06-27

Last Posted Date: 2013-04-22

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 37

Registration Number: NCT01381887

A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [11C] JNJ-42491293
Drug: [11C] JNJ-42491293 + JNJ-40411813

First Posted Date: 2011-05-25

Last Posted Date: 2011-07-22

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 20

Registration Number: NCT01359852

A Dose-Ranging Study of JNJ-40411813 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-40411813

First Posted Date: 2011-05-23

Last Posted Date: 2013-07-09

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 13

Registration Number: NCT01358006

The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Canagliflozin

First Posted Date: 2011-04-28

Last Posted Date: 2012-10-02

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 24

Registration Number: NCT01343290

A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Canagliflozin, 50 mg
Drug: Canagliflozin, 300 mg
Drug: Canagliflozin, 100 mg

First Posted Date: 2011-04-22

Last Posted Date: 2012-08-17

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 24

Registration Number: NCT01340677

A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: tapentadol (CG5503) ER two 100-mg TRF
Drug: tapentadol (CG5503) ER 25-mg TRF
Drug: tapentadol (CG5503) ER 50-mg TRF
Drug: tapentadol (CG5503) ER 100-mg TRF

First Posted Date: 2011-03-07

Last Posted Date: 2014-01-31

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 52

Registration Number: NCT01309425

A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Canagliflozin 300 mg once daily and HCTZ 25 mg once daily

First Posted Date: 2011-02-11

Last Posted Date: 2012-10-16

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 30

Registration Number: NCT01294631

An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus

Phase 4

Terminated

Conditions: Gastroparesis
Diabetes Mellitus

Interventions: Drug: Cisapride
Drug: Placebo

First Posted Date: 2011-01-31

Last Posted Date: 2011-01-31

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 4

Registration Number: NCT01286090

A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Canagliflozin 100 mg once daily and 50 mg twice daily
Drug: Canagliflozin 300 mg once daily and 150 mg twice daily

First Posted Date: 2011-01-31

Last Posted Date: 2012-03-13

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 34

Registration Number: NCT01286103

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy